Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,211 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06318169RecruitingPhase 3
Testing pegozafermin for MASH and liver fibrosis
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
Birmingham, AlabamaAges 18–80 - NCT07630649RecruitingPhase 2
Gene therapy for wet age-related macular degeneration in second eye
This study tests a one-time gene therapy injection (ixoberogene soroparvovec) in the second eye of people with wet age-related macular degeneration who have already responded well to anti-VEGF injections. The goal is to see if this gene therapy can help preserve or improve vision in that eye.
Phoenix, ArizonaAges 50 years+ - NCT07175428RecruitingPhase 2
Safety of a New Blood Thinner in AFib Patients
This study tests the safety of a new blood thinner for people with atrial fibrillation (AFib) who need long-term stroke prevention. If you qualify, the study will compare this medication to standard anticoagulation therapy.
Dothan, AlabamaAges 18 years+ - NCT06379789RecruitingPhase 1/Phase 2
Gene therapy for severe hemophilia B
This trial tests a new gene therapy (REGV131-LNP1265) that aims to let your body produce its own factor IX, reducing or stopping the need for regular infusions. It is for children and adults with severe hemophilia B who are already using factor IX replacement therapy.
Los Angeles, CaliforniaAges 2 years+ - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Goodyear, ArizonaAges 18 years+ - NCT07137910RecruitingPhase 2
Study of AHB-137 for chronic hepatitis B
This trial tests a new injection called AHB-137 for people with chronic hepatitis B. It aims to see if the drug is safe and helps control the virus.
Beijing, Beijing MunicipalityAges 18–65 - NCT06669247RecruitingPhase 1/Phase 2
Study of REGN7945 plus linvoseltamab for relapsed or refractory multiple myeloma
This study tests a new combination of two drugs (REGN7945 and linvoseltamab) for people with multiple myeloma that has come back or not responded to at least 3 prior treatments. The goal is to see if the combination is safe and effective, and it may offer a new option if other therapies have stopped working.
Sydney, New South WalesAges 18 years+ - NCT07225686RecruitingPhase 3
Maridebart Cafraglutide for sleep apnea in adults on CPAP
This study is testing whether a new medicine, called Maridebart Cafraglutide, can help people with obstructive sleep apnea who are already using a CPAP machine. The medicine may help with weight loss and potentially improve sleep apnea. Participants will either receive the medicine or a placebo (an inactive substance), and the study lasts for several months.
Northridge, CaliforniaAges 18–99 - NCT07745907RecruitingPhase 1
A first-in-human study of a new drug in healthy Chinese and Japanese adults
This trial tests a single dose of an investigational drug called AMG 691 in healthy Chinese and Japanese volunteers to see how it is processed by the body and how safe it is. This is an early-phase study, so it may help make future treatments safer for people of similar backgrounds.
Las Vegas, NevadaAges 18–60 - NCT07746167Recruiting
Pupil response study in healthy adults
This study looks at how your pupils react to light in healthy people. It may help doctors understand normal eye responses, which could improve future eye tests.
Washington D.C., District of ColumbiaAges 18–60 - NCT06701201Enrolling by invitation
Long-term follow-up for SynKIR CAR T cell patients
This study monitors participants who have received a SynKIR CAR T cell treatment in a past Verismo Therapeutics trial. It aims to track long-term health and safety outcomes over time.
Denver, ColoradoAges 18 years+ - NCT07197788Enrolling by invitation
Continued access to the Endogenex device study for type 2 diabetes
This trial offers continued access to the Endogenex system for people who were in the sham (placebo) group of the ReCET study and have completed their 12-month visit. It tests a device that treats the duodenum to improve blood sugar control.
Birmingham, AlabamaAges 22 years+ - NCT07573111RecruitingPhase 1
QUAIL-100 for Children With Blood Cancers After Stem Cell Transplant
This study tests a new experimental treatment called QUAIL-100 in children and young adults who have had a stem cell transplant for a serious blood cancer. The treatment is designed to help the immune system fight remaining cancer cells.
Palo Alto, CaliforniaAges 1.5 years–39 years - NCT07370207RecruitingPhase 2
Study of AHB-137 for HBeAg negative chronic hepatitis B
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
Fitzroy, VictoriaAges 18–65 - NCT07318610RecruitingPhase 3
Study of a new blood thinner in people with leg artery disease
This trial tests if a new blood-thinning drug (factor XI inhibitor) can prevent serious heart and leg problems in people who recently had a leg artery procedure. It compares the new drug to standard care for up to 3 years.
Alexander City, AlabamaAges 18 years+ - NCT07742735RecruitingPhase 3
Study of apraglutide for short bowel syndrome with intestinal failure
This study tests a new medicine called apraglutide, given as a shot, to see if it can help adults with short bowel syndrome and intestinal failure reduce their need for intravenous nutrition (parenteral support). The study compares apraglutide to a placebo (a shot with no medicine) to check if it is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06441331RecruitingPhase 1
Lu-177 edotreotide for children with SSTR-positive tumors
This trial tests a radioactive drug called Lu-177 edotreotide for children with a certain type of tumor (SSTR-positive) that hasn't responded to other treatments. The goal is to find the right dose and see how safe it is.
San Francisco, CaliforniaAges 2–18 - NCT06419205RecruitingPhase 2
ADX-097 for IgA nephropathy, lupus nephritis, or C3G
This study tests an experimental oral therapy called ADX-097 for people with three types of kidney disease: IgA nephropathy, lupus nephritis, or C3 glomerulopathy. The goal is to see if it’s safe and can help reduce kidney damage.
Lawrenceville, GeorgiaAges 16 years+ - NCT07734493RecruitingPhase 1
Study of a new drug for acute schizophrenia symptoms
This trial tests an experimental medicine, LTX-001, for people with schizophrenia who are currently having a sudden worsening of symptoms. It aims to see if the drug can help reduce these acute symptoms.
Little Rock, ArkansasAges 18–55 - NCT07564466RecruitingPhase 2
SKB571 treatment for gastrointestinal tumors
This study tests a new drug called SKB571 in people with stomach, intestinal, or related cancers. The goal is to see if it can shrink tumors and help patients live longer.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT07288177RecruitingPhase 2
A study of Rina-S for people with non-small cell lung cancer
This trial tests a new drug called Rina-S for people with non-small cell lung cancer that has spread or can't be removed by surgery. It aims to see if the drug can shrink tumors and how safe it is.
Fountain Valley, CaliforniaAges 18 years+ - NCT07166094RecruitingPhase 3
Rina-S vs standard therapy for advanced endometrial cancer
This trial tests a new drug called Rina-S (an antibody-drug conjugate) against standard treatments for advanced endometrial cancer that has returned after prior therapy. It may be an option if you have had at least 1 but no more than 3 prior treatments, including platinum chemo and immunotherapy.
Mobile, AlabamaAges 18 years+ - NCT07581002RecruitingPhase 2/Phase 3
New AML Treatment With Three Drug Combination Study
This study tests a new three-drug combination (pivekimab sunirine, venetoclax, and azacitidine) for newly diagnosed acute myeloid leukemia in patients who cannot tolerate intensive chemotherapy. The goal is to see if this combination is safe and effective at controlling the disease.
Phoenix, ArizonaAges 18 years+ - NCT07668999RecruitingPhase 1
Study of ZYG24004 for athlete's foot caused by fungus
This trial tests a new medication called ZYG24004 for athlete's foot (tinea pedis) caused by specific fungi. It may be a treatment option for people who have not had success with other antifungal treatments.
Beijing, Beijing MunicipalityAges 18–65
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,211 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.